Compare F.N.B. Corporation Common Stock (FNB) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs Eli Lilly And Co — how do they compare? F.N.B. Corporation Common Stock trades at $16.91 (market cap $6.07B), while Eli Lilly And Co trades at $1,216.51 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 171.3× F.N.B. Corporation Common Stock's market cap, and F.N.B. Corporation Common Stock pays the higher dividend (3.05%). Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Eli Lilly And Co for 94 Days on average.
| FNB | LLY | |
|---|---|---|
Market Cap | $6.07B | $1.04T |
Volume | 5,600,609 | 1,843,375 |
Sector | Financials | Health |
52-Week High | $19.49 | $1.28K |
52-Week Low | $14.65 | $799.57 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $10.61B | $1.09T |
Dividend Yield | 3.05% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
Eli Lilly (LLY) trades at $1,211.40, up 2.43% today, with a bullish technical outlook and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights pipeline advancements in weight-loss drugs, including EloraTZP's promising trial results.
Outlook remains positive given dominant market position in obesity and diabetes treatments, with analyst consensus price target of $1,350 implying ~11% upside. Key risks include competitive pressures from Novo Nordisk and regulatory hurdles. Earnings growth and pipeline catalysts support further appreciation, though high valuations warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
